Everett Harris & Co’s Biogen BIIB Stock Holding History

Everett Harris & Co’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-873	Closed	-$202K	–	271
2024 Q2	$202K	Buy	+873	New	+$190K	﹤0.01%	260
2024 Q1	–	Sell	-863	Closed	-$223K	–	270
2023 Q4	$223K	Hold	863	–	–	﹤0.01%	243
2023 Q3	$222K	Hold	863	–	–	﹤0.01%	234
2023 Q2	$246K	Hold	863	–	–	﹤0.01%	226
2023 Q1	$240K	Hold	863	–	–	﹤0.01%	234
2022 Q4	$239K	Hold	863	–	–	﹤0.01%	232
2022 Q3	$230K	Buy	+863	New	+$183K	﹤0.01%	236
2022 Q1	–	Sell	-863	Closed	-$207K	–	270
2021 Q4	$207K	Hold	863	–	–	﹤0.01%	257
2021 Q3	$244K	Hold	863	–	–	﹤0.01%	239
2021 Q2	$299K	Hold	863	–	–	﹤0.01%	229
2021 Q1	$241K	Hold	863	–	–	﹤0.01%	234
2020 Q4	$211K	Hold	863	–	–	﹤0.01%	240
2020 Q3	$245K	Hold	863	–	–	﹤0.01%	222
2020 Q2	$231K	Buy	+863	New	+$259K	0.01%	214

Other funds holding BIIB

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Everett Harris & Co's BIIB Position: Q3 2024 in Review

Everett Harris & Co sold out of Biogen (BIIB) in Q3 2024, closing a stake of 873 shares — an estimated $202K sold.

Everett Harris & Co first reported a position in BIIB in Q2 2020 and held it in 14 quarters. The position peaked at $299K in Q2 2021. 917 funds tracked by Wall St. Rank hold BIIB as of Q3 2024.

Everett Harris & Co reported no remaining Biogen position as of Q3 2024 after selling out during the quarter.
Everett Harris & Co sold 873 Biogen shares in Q3 2024, an estimated $202K.
Everett Harris & Co first reported a position in Biogen in Q2 2020 and held it in 14 quarters.
Everett Harris & Co's Biogen position peaked at $299K in Q2 2021.
917 funds tracked by Wall St. Rank held Biogen as of Q3 2024.

Based on Everett Harris & Co's 13F filing for Q3 2024, filed 18 Oct 2024.